Adjuvia Therapeutics is developing ATI-103, a proprietary nanoparticle formulation of astaxanthin designed to protect cells from oxidative stress caused by mitochondrial dysfunction. This therapeutic targets rare mitochondrial genetic diseases, such as Friedreich’s Ataxia and Leigh Syndrome, by enhancing cellular resilience and regulating critical metabolic and immune pathways.
Funding
Funding not disclosed
Founders
Product
Problem
Mitochondrial dysfunction leads to oxidative stress and dysregulation of metabolic and immune pathways, contributing to cell death, organ dysfunction, and degenerative diseases. Current treatments for rare mitochondrial genetic diseases, such as Friedreich’s Ataxia and Leigh Syndrome, are limited and do not effectively target the underlying cellular dysfunction. This results in high unmet medical needs for patients suffering from these conditions.
Solution
Adjuvia Therapeutics is developing ATI-103, a proprietary nanoparticle formulation of astaxanthin designed to protect cells from oxidative stress caused by mitochondrial dysfunction. ATI-103 has the ability to insert into the mitochondrial membrane, acting as a potent antioxidant. In addition to its antioxidant activities, ATI-103 regulates cell signaling pathways important for metabolic and immune homeostasis. The company's patented process extracts astaxanthin from natural sources into a nanoparticle formulation that enables maximum bioavailability and cellular activity following oral delivery.
Target Audience
The primary target audience includes patients suffering from rare mitochondrial genetic diseases, such as Friedreich’s Ataxia and Leigh Syndrome, and the healthcare providers who treat them.
Features
- Proprietary nanoparticle formulation of astaxanthin for enhanced bioavailability.
- Targets mitochondrial membrane to protect cells from oxidative stress.
- Regulates cell signaling pathways involved in metabolic and immune homeostasis.
- Orally administered therapy for improved patient compliance.
- Currently in IND-enabling studies for rare mitochondrial genetic diseases.